Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.7%

1 terminated out of 27 trials

Success Rate

94.1%

+7.6% vs benchmark

Late-Stage Pipeline

26%

7 trials in Phase 3/4

Results Transparency

38%

6 of 16 completed with results

Key Signals

6 with results94% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (4)
P 1 (5)
P 2 (7)
P 3 (7)

Trial Status

Completed16
Unknown4
Active Not Recruiting3
Withdrawn1
Terminated1
Recruiting1

Trial Success Rate

94.1%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT04537156Phase 3Active Not Recruiting

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT05087849Phase 1Completed

Intralesional HPV Vaccine for Condylomata

NCT02520986Not ApplicableRecruitingPrimary

Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma

NCT06197802Active Not Recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

NCT05056402Phase 3Active Not Recruiting

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

NCT03981822Phase 2CompletedPrimary

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT06297187Completed

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

NCT06430190Not ApplicableNot Yet RecruitingPrimary

Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata

NCT04782895Phase 3Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

NCT02710851Phase 2UnknownPrimary

Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

NCT00973856Not ApplicableCompleted

Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands

NCT02405520Phase 1CompletedPrimary

Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

NCT03158974Phase 2TerminatedPrimary

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

NCT03813940Phase 1CompletedPrimary

Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT03935204Phase 2CompletedPrimary

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT03546842Phase 3Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

NCT01796821Phase 2Completed

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

NCT03853785Phase 3UnknownPrimary

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

NCT00090285Phase 3CompletedPrimary

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

NCT02535104Phase 1CompletedPrimary

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Scroll to load more

Research Network

Activity Timeline